Overview

Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

Infections are a major and prevalent life-threatening complication among patients with myelodysplastic syndrome (MDS). Currently, the role of prophylactic antibacterial agents after chemotherapy in MDS patients remains controversial and there are no clinical guidelines for infection prophylaxis in this clinical setting. We will conduct a prospective study to evaluate the potential benefit of prophylactic antibacterial (Levofloxacin) on the rate of febrile episodes/infections in Azacytidine treated MDS patients.

Phase:

Phase 3

Details

Lead Sponsor:

Sheba Medical Center

Treatments:

Anti-Bacterial Agents
Azacitidine
Levofloxacin
Ofloxacin